Who are dorzolamide/timolol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): dorzolamide/timolol maleate fixed combination.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dorzolamide-timolol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

dorzolamide/timolol — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

dorzolamide/timolol (dorzolamide/timolol) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Carbonic anhydrase inhibitor / Beta-adrenergic antagonist combination. Area: Ophthalmology.

marketed Carbonic anhydrase inhibitor / Beta-adrenergic antagonist combination Carbonic anhydrase II / Beta-adrenergic receptors (β1 and β2) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

dorzolamide/timolol (dorzolamide/timolol) — CT Glaucoma Associates. Dorzolamide inhibits carbonic anhydrase to reduce aqueous humor production, while timolol blocks beta-adrenergic receptors to further decrease intraocular pressure.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
dorzolamide/timolol TARGET	dorzolamide/timolol	CT Glaucoma Associates	marketed	Carbonic anhydrase inhibitor / Beta-adrenergic antagonist combination	Carbonic anhydrase II / Beta-adrenergic receptors (β1 and β2)
dorzolamide/timolol maleate fixed combination	dorzolamide/timolol maleate fixed combination	Pharmaceutical Research Network	marketed	Carbonic anhydrase inhibitor / Beta-adrenergic antagonist combination	Carbonic anhydrase II; Beta-adrenergic receptors (β1 and β2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Carbonic anhydrase inhibitor / Beta-adrenergic antagonist combination class)

CT Glaucoma Associates · 1 drug in this class
Pharmaceutical Research Network · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). dorzolamide/timolol — Competitive Intelligence Brief. https://druglandscape.com/ci/dorzolamide-timolol. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing